drugset / Trial / NCT04806854

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

NCT04806854

Phase 2 Active not recruiting 24 enrolled Lumos Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).

Timeline

Start
2021-07-14
Primary completion
2030-04
Completion
2030-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LUM-201 Unknown 1.6 mg/kg Oral
Subject LUM-201 Unknown 3.2 mg/kg Oral

Indications